New Delhi, August 29, 2016: Jubilant Life Sciences Ltd, an integrated global Pharmaceuticals and Life Sciences Company, has announced that it has received Abbreviated New Drug Application (ANDA) final approval for Telmisartan Tablets, USP 20,40 and 80mg, the generic version of Micardis® Tablets of Boehringer Ingelheim Pharmaceuticals Inc., which is used for the treatment of hypertension.
As on June 30, 2016, Jubilant Life Sciences had a total of 770 filings for Oral Solids of which 578 have been approved in various regions globally. This includes 70 ANDAs filed in the US, of which 44 have been approved and 104 filings in Europe.
Corporate Comm India(CCI Newswire)
Noida, November 08, 2024: Esaote Group, a leading Italian innovator in medical imaging - ultrasound,…
Gurugram, November 08, 2024: AGI Greenpac Limited, a focused Packaging Products company, today announced its financial…
New Delhi, November 07, 2024: National Cancer Awareness Day serves as a poignant reminder of…
Coimbatore, November 07, 2024: The Arya Vaidya Pharmacy (Coimbatore) Ltd. (AVP), a pioneer in Ayurvedic…
New Delhi, November 06, 2024: Arla Foods Ingredients has launched a new whey protein hydrolysate…
By Dr. C N Patil, HOD and Lead Consultant - Medical Oncology & Haemato-Oncology, Aster…